Characteristic methylation profile in CpG island methylator phenotype‐negative distal colorectal cancers

Aberrant DNA methylation is involved in colon carcinogenesis. Although the CpG island methylator phenotype (CIMP) is defined as a subset of colorectal cancers (CRCs) with remarkably high levels of DNA methylation, it is not known whether epigenetic processes are also involved in CIMP‐negative tumors. We analyzed the DNA methylation profiles of 94 CRCs and their corresponding normal‐appearing colonic mucosa with 11 different markers, including the five classical CIMP markers. The CIMP markers were frequently methylated in proximal CRCs (p < 0.01); however, RASSF1A methylation levels were significantly higher in distal CRCs, the majority of which are CIMP‐negative (p < 0.05). Similarly, methylation levels of RASSF1A and SFRP1 in the normal‐appearing mucosae of distal CRC cases were significantly higher than those in the proximal CRC cases (p < 0.05). They were also positively correlated with age (RASSF1A, p < 0.01; SFRP1, p < 0.01). Microarray‐based genome‐wide DNA methylation analysis of 18 CRCs revealed that 168 genes and 720 genes were preferentially methylated in CIMP‐negative distal CRCs and CIMP‐positive CRCs, respectively. Interestingly, more than half of the hypermethylated genes in CIMP‐negative distal CRCs were also methylated in the normal‐appearing mucosae, indicating that hypermethylation in CIMP‐negative distal CRCs is more closely associated with age‐related methylation. By contrast, more than 60% of the hypermethylated genes in CIMP‐positive proximal CRCs were cancer specific (p < 0.01). These data altogether suggest that CpG island promoters appear to be methylated in different ways depending on location, a finding which may imply the presence of different mechanisms for the acquisition of epigenetic changes during colon tumorigenesis.

[1]  M. Toyota,et al.  Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. , 2009, Cancer research.

[2]  Martin Dugas,et al.  High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray , 2009, Molecular Cancer Research.

[3]  J. Issa,et al.  Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. , 2008, Carcinogenesis.

[4]  J. Issa Colon Cancer: It's CIN or CIMP , 2008, Clinical Cancer Research.

[5]  Yi Guo,et al.  An Sp1/Sp3 Binding Polymorphism Confers Methylation Protection , 2008, PLoS genetics.

[6]  S. Ogino,et al.  LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer , 2008, International journal of cancer.

[7]  S. Kakar,et al.  Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. , 2008, European journal of cancer.

[8]  M. Kloor,et al.  Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. , 2008, Gastroenterology.

[9]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[10]  W. Grady CIMP and colon cancer gets more complicated , 2007, Gut.

[11]  Li Zhang,et al.  Genome-Wide Profiling of DNA Methylation Reveals a Class of Normally Methylated CpG Island Promoters , 2007, PLoS genetics.

[12]  P. Gimotty,et al.  Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. , 2007, The Journal of molecular diagnostics : JMD.

[13]  Pang-Kuo Lo,et al.  HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition. , 2007, Cancer research.

[14]  T. Ushijima Epigenetic field for cancerization. , 2007, Journal of biochemistry and molecular biology.

[15]  Leopoldo Sarli,et al.  Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis , 2007, International Journal of Colorectal Disease.

[16]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[17]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[18]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[19]  J. Issa Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection , 2005, Nature Clinical Practice Oncology.

[20]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[21]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[22]  M. Toyota,et al.  CIMP, at last. , 2005, Gastroenterology.

[23]  J. Issa CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[24]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[25]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[26]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[27]  F. Guarner,et al.  Gut flora in health and disease , 2003, The Lancet.

[28]  B. Iacopetta Are there two sides to colorectal cancer? , 2002, International journal of cancer.

[29]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[30]  Michael J. Terry,et al.  A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes , 2002, Oncogene.

[31]  S. Clark,et al.  Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells , 2002, Oncogene.

[32]  S. Sukumar,et al.  Compromised HOXA5 function can limit p53 expression in human breast tumours , 2000, Nature.

[33]  David Joseph,et al.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.

[34]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[35]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[37]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Børresen-Dale,et al.  Different genetic pathways to proximal and distal colorectal cancer influenced by sex‐related factors , 1997, International journal of cancer.

[39]  Stefan U Kass,et al.  DNA methylation directs a time-dependent repression of transcription initiation , 1997, Current Biology.

[40]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[41]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[42]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[43]  E. Wynder,et al.  Environmental dietary factors in colorectal cancer some unresolved issues , 1992, Cancer.

[44]  J. Bufill,et al.  Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. , 1990, Annals of internal medicine.

[45]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.